Rotational stability of three toric IOL platforms
A multicentre randomised trial compared three toric IOLs after phacoemulsification in eyes with regular corneal astigmatism.
doi: 10.1097/j.jcrs.0000000000002023Latest reviews
One study, its results and limitations.
Presbyopia-correcting IOLs after cataract surgery: vision versus dysphotopsia
An overview of eight systematic reviews compared multifocal, trifocal, EDOF, accommodative and monofocal IOLs.
doi: 10.1136/bjo-2025-327363Enhanced monofocal IOLs: what changes after surgery
A meta-analysis compared enhanced and conventional monofocal IOLs after bilateral cataract surgery.
doi: 10.1038/s41433-025-03625-4Monofocal EDOF lens compared with a standard aspheric IOL
A multicentre randomised trial compared a monofocal extended-depth-of-focus lens with a standard aspheric monofocal IOL. The study explored functional vision, but its small sample limits broad conclusions.
doi: 10.1097/j.jcrs.0000000000001672Primary SLT for glaucoma: six-year LiGHT trial results
The LiGHT extension compared selective laser trabeculoplasty with pressure-lowering drops as initial treatment. Six-year data provide a clearer view of long-term disease control.
doi: 10.1016/j.ophtha.2022.09.009Low-concentration atropine for childhood myopia: the LAMP trial
LAMP assigned 438 children to three atropine concentrations or placebo. The effect was dose dependent, with 0.05% atropine producing the smallest refractive and axial-length changes at one year.
doi: 10.1016/j.ophtha.2018.05.029Why 0.01% atropine may not provide consistent myopia control
A US randomised trial in 187 children did not confirm the expected advantage of 0.01% atropine over placebo. The result cautions against assuming equal efficacy across doses and populations.
doi: 10.1001/jamaophthalmol.2023.2855DME with good vision: are immediate injections always necessary?
Protocol V compared aflibercept, laser and observation for centre-involved diabetic macular oedema with good visual acuity. At two years, immediate injections did not reduce vision loss significantly.
doi: 10.1001/jama.2019.5790AREDS2 at ten years: lutein and zeaxanthin instead of beta carotene
Long-term AREDS2 follow-up supported replacing beta carotene with lutein and zeaxanthin. The revised formula retained benefit for people at risk of late AMD without increasing lung-cancer risk.
doi: 10.1001/jamaophthalmol.2022.1640Lifitegrast for dry eye disease: OPUS-3 results
In the 12-week OPUS-3 trial, lifitegrast reduced eye-dryness symptoms more than placebo. A difference appeared by day 14, although not every secondary measure changed consistently.
doi: 10.1016/j.ophtha.2016.09.025